UPDATE: Separately, Perrigo Reports Suspension Of Sales Of Guaifenesin 600mg Extended Relaes Pending Resolution Of Challenges Related To Excipient Used In Production Of Product, Expected To Have Minimal Impact On Q4 EPS
Hal Lindon